Related Experiment Video
Updated: Feb 5, 2026

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma
Published on: April 17, 2013
[Identification of key pathways and drug repurposing for anaplastic thyroid carcinoma by integrated bioinformatics
Zongfu Pan1, Qilu Fang1, Yiwen Zhang1
1Department of Pharmacy, Zhejiang Cancer Hospital, Hangzhou 310022, China.
Objective:
To identify hub genes and key pathways associated with anaplastic thyroid carcinoma (ATC), and to explore possible intervention strategy.
Methods:
The differentially expressed genes (DEGs) in ATC were identified by Gene Expression Omnibus (GEO) combined with using R language; the pathway enrichment of DEGs were performed by using Kyoto Encyclopedia of Genes and Genomes (KEGG) and Gene Ontology (GO). The protein-protein interaction (PPI) network of DEGs was constructed by STRING database and visualized by Cytoscape. Furthermore, the hub genes and key nodes were calculated by MCODE. Finally, the drug repurposing was performed by L1000CDS2.
Results:
A total of 2087 DEGs were identified. The DEGs were clustered based on functions and pathways with significant enrichment analysis, among which PI3K-Akt signaling pathway, p53 signaling pathway, inflammatory response, extracellular matrix organization were significantly upregulated. The PPI network was constructed and the most significant three modules and nine genes were filtered. Twenty-two potential compounds were repurposed for ATC treatment.
Conclusions:
Using integrated bioinformatics analysis, we have identified hub genes and key pathways in ATC, and provide novel strategy for the treatment of ATC.
Insights
This study identified key genes and pathways in anaplastic thyroid carcinoma (ATC) using bioinformatics. Researchers also proposed potential drug repurposing strategies for ATC treatment.
Area of Science:
- Oncology
- Bioinformatics
- Genomics
Background:
- Anaplastic thyroid carcinoma (ATC) is an aggressive thyroid cancer subtype.
- Identifying molecular drivers and therapeutic targets is crucial for improving ATC patient outcomes.
Purpose of the Study:
- To identify hub genes and critical signaling pathways in ATC.
- To explore potential therapeutic intervention strategies for ATC through drug repurposing.
Main Methods:
- Differential gene expression analysis using Gene Expression Omnibus (GEO) data.
- Pathway enrichment analysis (KEGG, GO) and protein-protein interaction network construction (STRING, Cytoscape).
- Hub gene identification (MCODE) and drug repurposing (L1000CDS2).
Main Results:
- Identified 2087 differentially expressed genes (DEGs) in ATC.
- Significantly enriched pathways include PI3K-Akt signaling, p53 signaling, inflammatory response, and extracellular matrix organization.
- Filtered key modules and nine hub genes; identified 22 potential drug candidates for ATC treatment.
Conclusions:
- Integrated bioinformatics analysis successfully identified crucial hub genes and pathways in ATC.
- The study provides a novel strategy for ATC treatment, including potential drug repurposing targets.
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Key Techniques in Microbiology
Key Elements for Plant Nutrition
The Thyroid Gland
The follicles have a central cavity lined by simple cuboidal to squamous epithelial cells called follicular cells. These cells produce the glycoprotein...
Therapeutic Drug Monitoring: Drug Analysis Methods
C4 Pathway and CAM
C4 Pathway
The C4 pathway is used by plants such as...

